TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03747861

Intervention type: DEVICE
Group type: OTHER
Intervention: SenceBand
Description: Wristband for registration of ECG RR intervals for one hand, SenceBand will collect data from 5-minutes intervals each 30 minute within 24 hours
Study: NCT04226196

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of an intraocular lens
Description: Implantation of an intraocular lens Zeiss 409 MP into the capsular bag using an injector, after removing of the human crystalline lens.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of an intraocular lens
Description: Implantation of an intraocular lens Zeiss 409 MP into the capsular bag using an injector, after removing of the human crystalline lens.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of an intraocular lens
Description: Implantation of an intraocular lens Zeiss 409 MP into the capsular bag using an injector, after removing of the human crystalline lens.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of an intraocular lens
Description: Implantation of an intraocular lens Zeiss 409 MP into the capsular bag using an injector, after removing of the human crystalline lens.
Study: NCT01704599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humira Then Humira plus 3 B vitamins
Description: Humira alone for 16 weeks then Humira plus 100 mg daily pyridoxine, 5 mg daily folic acid and 1000 mcg daily cyanocobalamin
Study: NCT02885701

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Splint
Description: The no splint group received a soft dressing consisting of an occlusive petroleum gauze strip (Xeroform, Mansfield, MA) over the wound, one folded 4x4 gauze, and a single wrap of roll gauze around the hand, and the wrist was placed and secured by a Coban wrap (3M, St. Paul, MN). The dressing permitted wrist and finger motion. Patients were further instructed to remove the dressing at five days and place an adhesive bandage (Band-Aid, Johnson \& Johnson, New Brunswick, NJ) over the incision.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Removable Splint
Description: The removable splint group received a V-strap Wrist support (Medical Specialties, Inc., Charlotte, NC) placed over the identical soft dressing that was placed on the no splint group. The cock-up wrist splint was designed to keep the wrist fixed in a 20 degree extended wrist position. Patients were instructed to wear the splint for comfort as needed during day and night. While the patient was wearing the cock-up splint, only finger motion was permitted. Wrist motion was permitted when the cock-up splint was removed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-removable Splint
Description: The plaster non-removable splint group received an occlusive petroleum gauze strip placed over the wound, followed by a 4X4 gauze, and a Webril cotton roll wrap (Covidien, Inc., Covidien, Ireland). A 4- inch, 15-layer thick plaster splint was placed across the volar wrist and molded to keep the wrist in approximately 20 degrees of extension allowing full digital range of motion (ROM). The splint was to be kept dry and not removed by the patient.
Study: NCT00996398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tepid water immersion
Description: 28°C ± 1°C for the cold water immersion for 30 minutes to the level of the umbilicus
Study: NCT03441321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle and Values Intervention
Description: Participate in Facebook group focusing on avoiding tanning and promoting healthy body image

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Intervention
Description: Participate in Facebook group focusing on other health topics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT02516241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736 (Durvalumab)
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736 (Durvalumab)
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion
Study: NCT03615196

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: USB005 Ophthalmic Solution Placebo
Description: A clinical placebo formulated with the same excipients and packaged in the same container closure system as the active product, USB005 (aclerastide) Ophthalmic Solution.
Study: NCT00117598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus (CCI-779)
Description: Temsirolimus 175 mg IV once a week for 3 weeks; followed by 75 mg IV once a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus (CCI-779)
Description: Temsirolimus 175 mg IV once a week for 3 weeks; followed by 25 mg IV once a week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator's choice
Description: Any of the following single agent treatments:~1. Fludarabine 25 mg/m2 IV over 30 minutes daily for 5 consecutive days, every 28 days or oral administration, as appropriate.~2. Chlorambucil 0.1 (0.1-0.2) mg/kg PO daily for 3 to 6 weeks as required OR 0.4 (0.3 0.8) mg/kg PO every 21 to 28 days~3. Gemcitabine 1 gm/m2 IV over 30 minutes on days 1, 8 and 15 every 28 days or day 1 and day 8 every 21 days~4. Cyclophosphamide 300 (200-450) mg/m2 PO daily for 5 consecutive days every 21 to 28 days, OR 600 (400-1200) mg/m2 IV every 21 to 28 days~5. Cladribine 5 mg/m2 IV daily for 5 consecutive days, every 28 days for 2-6 cycles depending on response,~6. Etoposide 50 (50-150) mg/m2 IV daily for 3-5 days every 21 to 28 days OR 100 (50 300) mg/m2 PO daily for 3-5 days every 21 to 28 days~7. Prednisone 40 (20-60) mg/m2 PO daily or every other day~8. Dexamethasone 20(20-40) mg PO/IV daily for 5 consecutive days, every 14 - 28 day
Study: NCT03869528

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 sprays of 10% lignocaine
Description: 5 sprays of 10% lignocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 sprays of 10% lignocaine
Description: 10 sprays of 10% lignocaine
Study: NCT02501265

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline Standard Protocol
Description: 4 weeks pre-TQD: Start Placebo Varenicline~1 week prior to TQD: Switch to Active Varenicline~1 week prior to TQD: Start Placebo Bupropion Varenicline + Placebo Bupropion to 12 weeks post TQD

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patch Standard Protocol
Description: 4 weeks pre-TQD: Start Placebo Nicotine Patch TQD: Start active Nicotine Patch~1 week prior to TQD: Start Placebo Bupropion Nicotine Patch + Placebo Bupropion to 12 weeks post TQD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Adaptive Protocol
Description: VARENICLINE RESPONDER 4 weeks pre-TQD: Start Varenicline 2 weeks pre-TQD: DOES reduce cigs/day by \> 50% 1 week pre-TQD: Start Placebo Bupropion Varenicline + Placebo Bupropion to 12 weeks post TQD~VARENICLINE NON-RESPONDER 4 weeks pre-TQD: Start Varenicline 2 weeks pre-TQD: DOES NOT reduce cigs/day by \> 50%~1 week pre-TQD: Start active Bupropion Varenicline + Bupropion to 12 weeks post TQD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Adaptive Protocol
Description: NICOTINE PATCH RESPONDER 4 weeks pre-TQD: Start Patch 2 weeks pre-TQD: DOES reduce cigs/day by \> 50% 1 week pre-TQD: Start Placebo Bupropion Patch + Placebo Bupropion to 12 weeks post TQD~NICOTINE PATCH NON-RESPONDER 4 weeks pre-TQD: Start Patch 2 weeks pre-TQD: DOES NOT reduce cigs/day by \> 50%~1 week pre-TQD: Start Bupropion Patch + Bupropion to 12 weeks post TQD
Study: NCT04527302

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: ERP combined with high-definition active tDCS
Description: The active tDCS +ERP referred to a period of tDCS applied in the first 20 minutes of the ERP treatment (the tDCS device was activated when ERP began and deactivated automatically while ERP continued). The total treatment phase lasted eight weeks and included ten sessions with experienced psychotherapists following a specific manual for the tDCS+ERP treatment.~The tDCS device will deliver a direct current of 1.5mA during 20 minutes. Anode electrode will be localized in front of the mPFC on the FpZ point according to the EEG international reference. Four cathode electrodes will be placed around (i.e. AF7, AF8, F3, F4).

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: ERP combined with sham tDCS
Description: Patients will get the same CBT setting as the active tDCS group and they were applied the sham tDCS cocurrently with ERP. The sham tDCS device is the same as the active comparator's except that the sham tDCS will only deliver a current stimulation for the first and last 15 seconds in order to produce somatic sensation in patients similar to that induced by the active tDCS.
Study: NCT02634853

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Tavilermide Ophthalmic Solution
Description: 1% Tavilermide BID Dosing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ophthalmic Solution
Description: Vehicle Ophthalmic Solution
Study: NCT03681119

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dementia symptom management at home hospice edition
Description: Quality assurance performance improvement program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and Training
Description: Education and training
Study: NCT00356928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg/day intravenously (IV) on Days -2 and -1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor T cells
Description: CD8-depleted T cells given IV on Day 0. Dose levels are as follows (all doses in cells/kg):~Dose level 1: 1E5 CD4+ cells and less than 3.2E3 CD8+ cells Dose level 2: 1E6 CD4+ cells and less than 3.2E4 CD8+ cells Dose level 3: 1E7 CD4+ cells and less than 3.2E5 CD8+ cells Dose level 4: 5E7 CD4+ cells and less than 1.6E6 CD8+ cells
Study: NCT03332563

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention for chronic pain
Description: WebMAP is a technology-based cognitive-behavioral intervention program that teaches relaxation skills, pain coping strategies and parent behavioral and communication techniques to youth with chronic pain and their parents.
Study: NCT02739607

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic program
Description: This transdiagnostic program is based on the general Cognitive Behavioral Therapy (CBT) principles and targets core higher order factors such as negative affectivity and emotion dysregulation, using common intervention techniques applicable across disorders. The program was designed to directly address the aversive emotional experiences often reported by clients, hoping to reverse participants' maladaptive thinking style and dysfunctional behaviors.
Study: NCT01443104

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus-eluting stent with a bioresorbable polymer (Orsiro)
Description: Percutaneous coronary intervention with implantation of a sirolimus-eluting stent with a bioresorbable polymer for coronary artery disease

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus-eluting stent with a durable polymer
Description: Percutaneous coronary intervention with implantation of an everolimus-eluting stent with a durable polymer for coronary artery disease
Study: NCT00872651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/Timolol 0.5%
Description: Travoprost 0.004%/Timolol 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost 0.005% / Timolol 0.5%
Description: Latanoprost 0.005% / Timolol 0.5%
Study: NCT02942745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Betel Nut Cessation Social Support
Description: The cessation sessions will be led by trained facilitators over 22-day period. Session 1 (Day 1) includes a discussion of health risks associated with betel nut chewing, and introduction to self-monitoring and triggers logs. Session 2 (Day 8) includes a review of their logs, and discussions of lifestyle changes to assist cessation of betel nut chewing. Session 3 (Day 15) will be the quit day for chewers. Coping mechanisms and plans to maximize social support will be discussed. Session 4 (Day 18) will focus on quitting experiences. Facilitators will also review the negative health effects when wanting to chew again. Discussion on quitting experiences will continue in Session 5 (Day 22). Facilitators will also address those who have experienced relapse, and how to manage relapse.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Betel Nut Cessation Booklet
Description: Participants will receive minimal intervention via a single booklet that contains all the information offered in the experimental group, minus the social support sessions. The participants will meet with study staff individually at a designated office in Guam or Saipan to receive the betel nut cessation booklet, complete three assessments (baseline, 22 days, 6 months), and provide saliva samples.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Betel Nut Cessation Booklet
Description: Participants will receive minimal intervention via a single booklet that contains all the information offered in the experimental group, minus the social support sessions. The participants will meet with study staff individually at a designated office in Guam or Saipan to receive the betel nut cessation booklet, complete three assessments (baseline, 22 days, 6 months), and provide saliva samples.
Study: NCT02093013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated care program
Description: Integrated care program meant in effect, calling on the family medicine group (FMG) nurses to evaluate and support asthmatic patients. The FMG and asthma education centre (AEC) nurses received special training and followed a protocol based on the theoretical model and the Canadian asthma management recommendations then in force. The protocol had five main aspects: 1) asthma assessment, 2) self-management, 3) environment and lifestyle, 4) collaborative care plan, and 5) information sharing and follow-up.
Study: NCT00841594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitroglycerin 0.9 % (MXQ-503)
Description: MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin ointment 2%, USP
Description: MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.
Study: NCT04132362

Intervention type: BEHAVIORAL
Intervention: Personalised music listening
Description: People will be sequentially recruited to discover their favourite music playlist, monitor their emotional responses to specific songs and explore the impact of listening to the music, on their behavioural and psychological symptoms. This will be done through a one hour music listening session, to discover the top 10-20 songs they respond to. It will then be followed by multiple shorter music listening sessions, initiated by the dementia resident themselves or their carer, where they listen to their favourite songs during their day, before difficult moments of care or during visits with their families.

Intervention type: BEHAVIORAL
Intervention: Using fMRI to investigate the effect of listening to personalised music evoking positive emotional response on brain activation
Description: 12 of the recruited participants, who have symptoms and signs of mild to moderate dementia will be invited to take part in this sub-study. Using an amended version of a previously employed fMRI paradigm, each study participant will be presented inside the MRI scanner with short 30 second epochs of music (identified as evoking a positive or neutral emotional response) in a block design. Each 30 second epoch of music will be followed by a 16 second period when participants will be asked to rate subjective changes in their affective state using a computerised visual analogue scale. Epochs of positive emotional stimuli will alternate with epochs of neutral emotional stimuli in a counterbalanced order of presentation in 2 runs of 10 epochs each (5 positive and 5 neutral in each run).

Intervention type: BEHAVIORAL
Intervention: Personalised music listening in the community
Description: 1000 families affected by dementia will be invited to use our WebApp to create a personalised playlist for their loved one with dementia and share their perceptions of how the music has affected the well-being of their loved one.
Study: NCT02671136

Intervention type: DEVICE
Group type: OTHER
Intervention: Hyperbaric Oxygen therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Wound Therapies

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Wound Therapies
Study: NCT02336490

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Discharge Medication Delivery Service
Description: hospital-owned outpatient pharmacy fills and delivers discharge medications to patients in their rooms prior to discharge
Study: NCT01142102

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: A radical dose of radiotherapy to be delivered to the entire bladder volume: 64Gy in 32 fractions over 6 weeks and 2 treatment days.~* Conventional plan is used to deliver treatment for fractions 1 to 7 using a standard planning approach and a CTV to PTV margin of 1.5cm.~* Adaptive plan is used to deliver treatment for fractions 8 through 32 using the same standard techniques as for fractions 1 to 7 but using one of three specific CTV volumes,namely: small, average or large. In all these cases the CTV to PTV margin is 0.7cm. Image guidance using a treatment unit based verification CT unit (Cone Beam CT or CT on Rails)based on soft tissue delineation is used to position the treatment fields and select the plan to best cover the CTV.
Study: NCT04827784

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: local anaesthetic injection
Description: The head and neck of the condyle were detected by palpating the pretragal area. Then, the needle was inserted anterior to the junction of the tragus and the lobule. After 0.5 ml the solution was subcutaneously infiltrated, the needle was protruded until it touched the neck of the condyle. Aspiration was performed to avoid intravenous injections, and the remaining solution was injected thereafter.
Study: NCT00996944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole immediate release (IR)
Description: Subjects completing the screening period will be randomized (1:1) to receive the IR or placebo for 12 weeks. The treatment will be started at the initial dose of 0.25 mg/day within 1 to 3 hours before bedtime. The maximum available dose is 3 mg/day. For all subjects completing short-term period and entering the long-term treatment period, the open-label treatment will be started from IR 0.25 mg/ day regardless of dose levels during short-term period. The dose will be upward titrated from 0.25 mg/day to 0.5 mg/day and after that in increments of 0.5 mg/day until sufficient efficacy is obtained (targeting much improved or very much improved in the CGI-I) without safety/tolerability problem.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects completing the screening period will be randomized (1:1) to receive the IR or placebo for 12 weeks. The treatment will be started at the initial dose of 0.25 mg/day within 1 to 3 hours before bedtime.
Study: NCT01310894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOOKAD® Soluble
Description: TOOKAD® Soluble-VTP procedure will consist of an IntraVenous (IV) administration to patients using a 753nm laser light at a fixed power of 150mW/cm and a fixed energy at 200J/cm delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance
Study: NCT03910907

Intervention type: DRUG
Intervention: Comparison of two standard of care regimens
Description: Treatment according to results of laboratory detection of resistance markers

Intervention type: DRUG
Intervention: Comparison of two standard of care regimens
Description: Treatment according to results of laboratory detection of resistance markers
Study: NCT02027142

Intervention type: OTHER
Intervention: Pittsburgh Sleep Quality Index.
Description: Pittsburgh Sleep Quality Index is an effective instrument used to measure the quality and patterns of sleep of patients. It allows evaluating poor from good sleep by assessing seven domains. A total score ≤ 5 indicated good sleep quality while a total score \> 5 was indicated poor sleep quality.

Intervention type: OTHER
Intervention: Pittsburgh Sleep Quality Index.
Description: Pittsburgh Sleep Quality Index is an effective instrument used to measure the quality and patterns of sleep of patients. It allows evaluating poor from good sleep by assessing seven domains. A total score ≤ 5 indicated good sleep quality while a total score \> 5 was indicated poor sleep quality.

Intervention type: OTHER
Intervention: Epworth sleepiness scale.
Description: Epworth sleepiness scale is an 8-item questionnaire developed to measure average daytime sleepiness. A total score ≥ 10 indicates excessive daytime sleepiness.

Intervention type: OTHER
Intervention: Epworth sleepiness scale.
Description: Epworth sleepiness scale is an 8-item questionnaire developed to measure average daytime sleepiness. A total score ≥ 10 indicates excessive daytime sleepiness.

Intervention type: OTHER
Intervention: Insomnia Severity Index.
Description: Insomnia Severity Index is a 7-item questionnaire developed to measure insomnia. A total score between 0 and 7 correspond to not clinically significant insomnia, between 8 and 14 to subthreshold insomnia, between 15 and 21 to clinical insomnia (moderate), between 22 and 28 to clinical insomnia (severe).

Intervention type: OTHER
Intervention: Insomnia Severity Index.
Description: Insomnia Severity Index is a 7-item questionnaire developed to measure insomnia. A total score between 0 and 7 correspond to not clinically significant insomnia, between 8 and 14 to subthreshold insomnia, between 15 and 21 to clinical insomnia (moderate), between 22 and 28 to clinical insomnia (severe).

Intervention type: OTHER
Intervention: The Endometriosis Health Profile.
Description: The Endometriosis Health Profile is a patient generated instrument that evaluates disease-specific health-related quality of life in patients with endometriosis. The questionnaire is administrable to all patients with endometriosis and it consists in 30 items divided in 5 domains (pain, control and powerlessness, emotional well-being, social support and self-image). Each scale for each domain is comprised between 0 (indicating the best health status) and 100 (indicating the worst health status).